PHARMACEUTICALS
Each of JSE-listed Adcock Ingram’s business units had posted “solid performances” in the six months to December 31, achieving good growth in turnover and good cost control. The group on Wednesday reported a 70% increase in earnings a share and a 49% increase in headline earnings a share for the six months under review.
This content is only available to subscribers.
Forgot your password? Click here
Don't have any login details?
Free Trial Access